Robert E. Conway is Director at ARCA biopharma, Inc. (ABIO). They have made 16 open-market trades across 3 companies since 2015, most recently 2024-05-20.
CIK 0001184334
16 open-market purchases totalling $804K since 2015, never a sale. Across 12 scored buys the stock is down 1.6% at ninety days, and 8.7 points behind the S&P over the same stretch.
16 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 31% | 33% |
| Avg Move | +0.5% | +1.6% | -1.6% |
| Alpha | +0.3% | -0.5% | -8.7% |
| Scored | 16 | 16 | 12 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALPN | SELL · Routine | 2021-09-23 | 2021-09-27 | $10.08 | $151K | +12.3% | +7.0% | +26.4% |
| ALPN | BUY | 2021-09-23 | 2021-09-27 | $10.08 | $151K | +12.3% | +7.0% | +26.4% |
| ALPN | BUY | 2021-09-21 | 2021-09-23 | $9.80 | $98K | +10.6% | -0.3% | +25.1% |
| ABIO | BUY | 2021-05-12 | 2021-05-13 | $3.19 | $32K | +4.1% | +24.2% | -3.2% |
| ABIO | BUY | 2021-05-05 | 2021-05-06 | $3.23 | $32K | +7.0% | +15.9% | -6.4% |
| ABIO | BUY | 2020-12-18 | 2020-12-21 | $4.16 | $42K | -4.8% | +5.5% | -2.5% |
| ALPN | BUY | 2020-11-19 | 2020-11-23 | $8.03 | $80K | +21.9% | +95.7% | +43.2% |
| ABIO | BUY | 2020-09-25 | 2020-09-25 | $4.28 | $21K | +2.8% | -13.3% | -7.9% |
| ABIO | BUY | 2020-09-22 | 2020-09-24 | $4.66 | $14K | +24.5% | -3.8% | +4.8% |
| ABIO | BUY | 2020-09-21 | 2020-09-21 | $4.77 | $48K | -6.7% | -14.1% | -10.1% |
| ABIO | BUY | 2017-07-14 | 2017-07-17 | $2.49 | $25K | -16.7% | -52.9% | -46.1% |
| NVLS | BUY | 2017-05-09 | 2017-05-10 | $2.34 | $12K | -1.6% | -7.0% | N/A |
| NVLS | BUY | 2017-05-08 | 2017-05-11 | $2.28 | $34K | -2.1% | -7.0% | N/A |
| NVLS | BUY | 2017-05-05 | 2017-05-09 | $2.30 | $46K | -1.3% | -3.4% | N/A |
| NVLS | BUY | 2017-05-04 | 2017-05-08 | $2.26 | $23K | +0.4% | -0.4% | N/A |
| ABIO | BUY | 2017-03-24 | 2017-03-27 | $2.59 | $65K | -7.5% | -3.8% | -5.7% |
| NVLS | BUY | 2015-12-09 | 2015-12-11 | $8.10 | $81K | -34.1% | -17.4% | -37.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.